Reduction Of Risk Of Stroke And Systemic Embolism In Nonvalvular Atrial Fibrillation: ELIQUIS® (apixaban) is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
About Company
Contact Us
FAQ